Hikma

Hikma and Arecor Expand Collaboration

Retrieved on: 
Tuesday, October 20, 2020
Hikma

The agreement builds on Hikma and Arecor's first product co-development agreement, which was announced on 9 January 2020.

Key Points: 
  • The agreement builds on Hikma and Arecor's first product co-development agreement, which was announced on 9 January 2020.
  • "We are pleased to expand on our partnership with Arecor and add a new ready-to-administer product to our growing pipeline of differentiated injectable medicines," said Riad Mishlawi, President, Hikma Injectables.
  • Sarah Howell, Chief Executive Officer of Arecor, added: "Our track record in developing ready-to-administer medicines is further strengthened by this second agreement with Hikma.
  • We look forward to developing this relationship with Hikma further and progressing these products to market as part of this collaboration."

Hikma receives favourable court ruling for its generic Vascepa®

Retrieved on: 
Thursday, September 3, 2020
Health, Articles, Hikma Pharmaceuticals, Hikma, HIK, Health technology, Pharmaceutical industry in China, Pharmaceutical industry, Amarin Corporation

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.

Key Points: 
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.
  • For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them.
  • We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world.
  • For more information, please visit: www.hikma.com
    View original content to download multimedia: http://www.prnewswire.com/news-releases/hikma-receives-favourable-court-...
    SOURCE Hikma Pharmaceuticals USA Inc.

Hikma Ventures Participates in CAD4.0 million Series A Financing Round for SeamlessMD to Expand Digital Patient Engagement Leadership

Retrieved on: 
Wednesday, August 26, 2020
Hikma Pharmaceuticals, Hikma, Health, Cerner, HIK, Italian Academy of Orthodontic Technology, Heal, Subscription, Companies

LONDON, Aug. 26, 2020 /PRNewswire/ --Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD .

Key Points: 
  • LONDON, Aug. 26, 2020 /PRNewswire/ --Hikma Pharmaceuticals PLC (Hikma) announces that its venture capital arm, Hikma Ventures has participated in a CAD4.0 million Series A round of financing for SeamlessMD .
  • The round was led by MEDTEQ, bringing the company's total funding to CAD7.4 million.
  • Anges Qubec, AIoT Health, and health IT entrepreneur Sanjay Malaviya also participated in the oversubscribed round.
  • SeamlessMD's financing follows a period of establishing category leadership, having become the first digital patient engagement platform to hold validated, turn-key integrations with leading electronic health record companies Epic and Cerner.

Premier Inc. ProvideGx™ Program Partners with Hikma Pharmaceuticals to Secure the Supply of Two Drugs Essential for COVID-19 Patient Care

Retrieved on: 
Thursday, May 28, 2020
Medical Supplies, Medical devices, Health, Infectious diseases, Practice Management, Pharmaceutical, Drugs, Amiodarone, Hepatotoxins, RTT, Hikma Pharmaceuticals, Hikma, Medicine, Medical specialties

(NASDAQ: PINC), through its ProvideGx program, has partnered with Hikma Pharmaceuticals PLC (Hikma, Group) to supply amiodarone and sterile water to healthcare providers, helping to stabilize the long-term supply of two medications vital for COVID-19 patient care.

Key Points: 
  • (NASDAQ: PINC), through its ProvideGx program, has partnered with Hikma Pharmaceuticals PLC (Hikma, Group) to supply amiodarone and sterile water to healthcare providers, helping to stabilize the long-term supply of two medications vital for COVID-19 patient care.
  • Sterile water is used to reconstitute many medications for injection, including remdesivir, which has been shown to speed COVID-19 recovery times.
  • Premiers ProvideGx program identifies safe, high-quality supply sources for drugs that are or may be at risk of being added to the national drug shortage list.
  • Premier currently is targeting more than 50 critical drugs to secure for healthcare providers across the nation.

Hikma launches employee matching donation campaign to support local US food banks and pantries

Retrieved on: 
Monday, May 11, 2020
Food bank, Hikma, HIK

EATONTOWN, N.J., May 11, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, announces the launch of an employee matching donation campaign to support local food banks and pantries in the US communities in which Hikma operates.

Key Points: 
  • EATONTOWN, N.J., May 11, 2020 /PRNewswire/ -- Hikma Pharmaceuticals PLC, the multinational generic pharmaceutical company, announces the launch of an employee matching donation campaign to support local food banks and pantries in the US communities in which Hikma operates.
  • Hoffmann continued, "We are proud to launch this campaign, which will support our local food banks and pantries as they face the challenges of meeting the sudden rise in local community members seeking support.
  • The employee matching donation campaign builds on Hikma's existing relationships with the following food banks and pantries in each of its local markets:
    Bedford, OH: The Emergency Assistance Center (TEAC) has provided food, clothing and personal hygiene items to Northern Summit County neighbors in need for more than 25 years.
  • Every dollar raised will go directly to each organizations' COVID-19 relief efforts and will be used to support local families in need.

Altoida Inc. Secures Investment from Hikma Ventures to Drive Better Clinical Outcomes for Brain Diseases

Retrieved on: 
Monday, May 4, 2020
Branches of biology, Biomarkers, Biology, Life sciences, Cell biology, Hikma, HIK, Corporate venture capital

Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy."

Key Points: 
  • Hikma Ventures is the perfect addition to our investor syndicate and an important partner as we continue to execute on our clearly defined commercialization strategy."
  • Altoida leverages predictive digital biomarkers to drive better clinical outcomes for brain disease.
  • "We are excited to invest in Altoida and their digital health technology, which is helping patients and healthcare providers by reinventing digital biomarkers to drive better clinical outcomes for brain disease," said Lana Ghanem, Managing Director of Hikma Ventures.
  • Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.

Hikma and Arecor announce exclusive agreement to develop and commercialise ready-to-use medicine using Arestat™ technology

Retrieved on: 
Thursday, January 9, 2020
Hikma, HIK, Food and Drug Administration, Health, Articles

Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.

Key Points: 
  • Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.
  • "We are proud to be working with Hikma," said Sarah Howell, Chief Executive Officer of Arecor.
  • We look forward to the joint development of this first product as part of a broad collaboration with Hikma."
  • Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world.

Arecor and Hikma Announce Exclusive Agreement to Develop and Commercialise Ready-To-Use Medicine Using Arestat™ Technology

Retrieved on: 
Thursday, January 9, 2020
Hikma, Food and Drug Administration, Health, Articles

Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.

Key Points: 
  • Hikma will seek approval for the product under the U.S. Food and Drug Administration's 505(b)(2) regulatory pathway, with filing expected in 2021.
  • "We are proud to be working with Hikma," said Sarah Howell, Chief Executive Officer of Arecor.
  • We look forward to the joint development of this first product as part of a broad collaboration with Hikma."
  • Arecor retains the right to develop and commercialise the product in certain markets outside the US.

Civica Rx and Hikma Announce Shipments of Heparin and Seven Other Essential Injectable Medicines

Retrieved on: 
Tuesday, December 10, 2019
Oncology, Health, Hospitals, Surgery, Pharmaceutical, Cardiology, RTT, Civica Rx, Civica Rx, Hikma

Under the partnership with Civica Rx, announced last July, Hikma will produce 14 essential sterile injectable medications for Civica, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's National Drug Code (NDC) and label.

Key Points: 
  • Under the partnership with Civica Rx, announced last July, Hikma will produce 14 essential sterile injectable medications for Civica, using Hikma's Abbreviated New Drug Applications (ANDAs) and Civica's National Drug Code (NDC) and label.
  • Hikma is the third largest US supplier by volume of generic injectable medicines with a growing portfolio of more than 100 injectable products.
  • Today, one in every six generic injectable medicines used in US hospitals is a Hikma product.
  • Civica aims to stabilize the supply of antibiotics, anesthetics, cardiac medications, pain management medications, and other essential sterile injectable medicines used in hospitals daily.

Hikma Ventures leads Series A financing for development of Winterlight Labs' AI vocal technology to detect central nervous system disorders and track efficacy of treatments

Retrieved on: 
Monday, November 18, 2019
Cognitive disorders, Learning disabilities, Psychiatric diagnosis, RTT, Aging-associated diseases, Hikma, Psychiatry, Dementia, HIK, Health, Cognition

Lana Ghanem, Managing Director of Hikma Ventures, said, "We are very excited to enter into the field of vocal diagnostics by leading the investment in Winterlight Labs.

Key Points: 
  • Lana Ghanem, Managing Director of Hikma Ventures, said, "We are very excited to enter into the field of vocal diagnostics by leading the investment in Winterlight Labs.
  • "The technology our team is creating will reshape the way healthcare systems track, screen for and assess the effectiveness of treatments for various central nervous system diseases."
  • Founded in August 2015, Hikma Ventures operates as the corporate venture capital arm of Hikma Pharmaceuticals.
  • By analysing speech alone, the technology can detect cognitive impairment associated with dementia and mental illness as track the efficacy of related treatments.